Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Breakthrough Results from Study C602

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a trailblazer in the biopharmaceutical industry, recently unveiled its promising top-line results from the randomized withdrawal phase of Study C602. This pivotal study delved into the long-term therapeutic effects of DCCR (Diazoxide Choline) Extended-Release tablets, specifically targeting Prader-Willi syndrome (PWS).

Soleno CEO’s Enthusiastic Remarks

Anish Bhatnagar, M.D., the dynamic CEO of Soleno, couldn’t hide his enthusiasm about the significant outcomes of the study. “The results from the randomized withdrawal phase of Study C602 have surpassed our expectations,” he remarked. “These findings lay a robust foundation for our planned New Drug Application (NDA) submission to the U.S. FDA in the coming year.”

Bhatnagar also took a moment to acknowledge the relentless efforts of the patients, their families, investigators, study site personnel, and the advocacy community. He further highlighted the unwavering dedication of the entire Soleno team towards the DCCR development program. “Our primary objective remains to expedite the delivery of DCCR, upon approval, as a potent and safe therapeutic option for individuals grappling with PWS,” he added.

FDA’s Positive Nod

The U.S. Food and Drug Administration (FDA) has previously signaled its optimism regarding the data from this study, hinting at its potential to back an NDA submission for DCCR. Notably, DCCR has already clinched the Orphan Drug designation for PWS treatment in both the U.S. and E.U. Furthermore, it has been honored with the Fast Track designation by the FDA, underscoring its potential significance in the medical community.

In-depth Look at Study Design

Diving deeper into the study’s design, the C602 randomized withdrawal period was meticulously crafted as a multi-center, double-blind trial. It encompassed 77 patients, all of whom showcased hyperphagia-related behaviors. These behaviors were meticulously assessed using the hyperphagia questionnaire for clinical trials (HQ-CT). The findings were nothing short of remarkable, with a pronounced difference in the HQ-CT total score of 5.0 at week 16 (p=0.0022) favoring DCCR.

The secondary endpoints also painted a rosy picture, indicating a strong inclination towards the efficacy of DCCR. Moreover, the drug’s safety profile remained impeccable, with patients reporting no new or unexpected health concerns.

Financial Milestones for Soleno

On the financial front, Soleno Therapeutics made headlines in December 2022 when it forged a Securities Purchase Agreement with renowned entities like Nantahala Capital Management, LLC, Abingworth LLP, and Vivo Capital, LLC. This strategic move is anticipated to channel gross proceeds of up to $60 million into Soleno’s coffers. Following the release of the positive top-line data from Study C602, the investors are poised to exercise Tranche A warrants, translating to a windfall of approximately $15 million for Soleno.

As the biopharmaceutical world keenly watches, Soleno Therapeutics is poised to redefine the therapeutic landscape for Prader-Willi syndrome.

Disclosure: Neither Matt Rego nor Spotlight Growth have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

The post Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.